Tauroursodeoxycholate prevents taurolithocholate-induced cholestasis and toxicity in rat liver.
Ursodeoxycholate has been advocated for the treatment of cholestatic liver diseases. The coinfusion of tauroursodeoxycholate with taurolithocholate in the perfused rat liver completely prevented the decrease of bile flow and the increase of oxygen uptake found with taurolithocholate only. Bile flow and bile salt secretion were increased with the coinfusion of both bile acids as compared with the infusion of tauroursodeoxycholate only (+4.30 microliters/g liver per 30 min) with 16 and 32 mumol/l tauroursodeoxycholate (+1.55 microliters/g liver per 30 min with 80 and 160 mumol/l). Morphological examination revealed a 50% decrease of the number of necrotic cells in the periportal area. Tauroursodeoxycholate did not inhibit the uptake of taurolithocholate, but increased its transcellular passage and biotransformation. Thus, tauroursodeoxycholate prevents taurolithocholate-induced cholestasis and liver cell toxicity probably by an intracellular mechanism.
Schölmerich
J
J
Department of Internal Medicine, University of Freiburg, Federal Republic of Germany.
Baumgartner
U
U
Miyai
K
K
Gerok
W
W
D000818:Animals; D002635:Chenodeoxycholic Acid / Q000031:analogs & derivatives*; D002779:Cholestasis / Q000139:chemically induced / Q000517:prevention & control*; D008095:Lithocholic Acid / Q000031:analogs & derivatives*; D008099:Liver / Q000187:drug effects* / Q000473:pathology; D051381:Rats; D013655:Taurochenodeoxycholic Acid / Q000627:therapeutic use*; D013658:Taurolithocholic Acid / Q000009:adverse effects* / Q000633:toxicity
D002635:Chenodeoxycholic Acid; D013655:Taurochenodeoxycholic Acid; D013658:Taurolithocholic Acid; D008095:Lithocholic Acid; C031655:ursodoxicoltaurine